ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2008;86:228-233. doi:10.1016/j.athoracsur.2008.01.019
© 2008 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Nicola Santelmo
Xavier Ducrocq
Jean-Marie Wihlm
Gilbert Massard
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Mansour, Z.
Right arrow Articles by Massard, G.
PubMed
Right arrow Articles by Mansour, Z.
Right arrow Articles by Massard, G.
Related Collections
Right arrow Lung - cancer
Right arrowRelated Article

Original Articles: General Thoracic

Persistent N2 Disease After Induction Therapy Does Not Jeopardize Early and Medium Term Outcomes of Pneumonectomy

Ziad Mansour, MDa, Evgenia A. Kochetkova, MD, PhDa, Nicola Santelmo, MDa, Xavier Ducrocq, MDa, Elisabeth Quoix, MD, PhDb, Jean-Marie Wihlm, MDa, Gilbert Massard, MDa,*

a Thoracic Surgery Service, Strasbourg University Hospital, Strasbourg, France
b Department of Pulmonology, Strasbourg University Hospital, Strasbourg, France

Accepted for publication January 7, 2008.

* Address correspondence to Dr Massard, Service de Chirurgie Thoracique, Hôpitaux Universitaires de Strasbourg, 67091 Strasbourg, France (Email: gilbert.massard{at}chru-strasbourg.fr).

Background: Operative management of patients with persistent N2 disease after induction therapy is still debated.

Methods: One hundred fifty-three consecutive patients underwent pneumonectomy from January 1999 until July 2005; 28 patients (18.3%) had persistent N2 disease after induction therapy (group 1), 32 patients (20.9%) had pathologic stage N0 or N1 after induction therapy (group 2), and 93 patients (60.8%) with pathologic N2 disease underwent immediate surgery (group 3). Short-term end points were operative mortality at 30 and 90 days and major complications. Long-term end points were 5-year survival and disease-free survival rates.

Results: Demographics of the three groups were similar (age, sex, side of operation, type of chemotherapy, smoking status, and comorbidity such as coronary artery disease, diabetes, and chronic obstructive pulmonary disease). Thirty-day postoperative mortality was 10.7% in group 1, 3.1% in group 2 (p = 0.257), and 4.3% in group 3 (p = 0.201); 90-day postoperative mortality was 10.7% in group 1, 12.5% in group 2 (p = 0.577), and 9.7% in group 3 (p = 0.558). Incidence of major postoperative complications was similar. Five-year survival rate was 32.2% (median, 28 months; 95% confidence interval, 7 to 43) in group 1, 34.8% (median, 27 months; 95% confidence interval, 7 to 47) in group 2 (p = 0.685), and 12.4% (median, 15 months; 95% confidence interval, 11 to 19) in group 3 (p = 0.127). No statistical difference was found in terms of 5-year event-free survival, or regarding the side of pneumonectomy.

Conclusions: Our results suggest that pneumonectomy is justified in patients with persistent N2 disease after induction chemotherapy.


Related Article

Invited Commentary
Pierre-Emmanuel Falcoz
Ann. Thorac. Surg. 2008 86: 233-234. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
P.-E. Falcoz
Invited commentary.
Ann. Thorac. Surg., July 1, 2008; 86(1): 233 - 234.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The Society of Thoracic Surgeons.